Share on StockTwits

Uniqure BV (NASDAQ:QURE)‘s stock had its “buy” rating restated by investment analysts at Jefferies Group in a note issued to investors on Wednesday. They currently have a $22.00 price target on the stock, down from their previous price target of $23.00. Jefferies Group’s price target suggests a potential upside of 96.78% from the company’s current price.

Shares of Uniqure BV (NASDAQ:QURE) traded down 0.09% during mid-day trading on Wednesday, hitting $11.17. The stock had a trading volume of 1,380 shares. Uniqure BV has a 52 week low of $8.29 and a 52 week high of $18.75. The stock’s 50-day moving average is $10.95 and its 200-day moving average is $12.20. The company’s market cap is $196.5 million.

Uniqure BV (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, September 2nd. The company reported ($1.35) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.55) by $0.80. Analysts expect that Uniqure BV will post $-2.42 EPS for the current fiscal year.

Uniqure BV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases.

Receive News & Ratings for Uniqure BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure BV and related companies with Analyst Ratings Network's FREE daily email newsletter.